One report, one million physicians

With the importance of equity, inclusion, diversity and belonging taking center stage in the national debate on healthcare, HealthVerity realized that its real-world data (RWD) ecosystem was ideally suited to respond to the challenge. The HealthVerity Provider Diversity Index (PDI) is the only nationally syndicated study that leverages medical, pharmacy and consumer data to compute the racial diversity of patients for over 1 million physicians, all in a HIPAA-compliant manner. The PDI has become the definitive guide for a wide range of diversity-challenged endeavors, such as clinical trial investigator recruiting and health plan network building.

Broaden choices for clinical trial investigators

Instantly assess the demographic composition of a healthcare provider’s patient population, including race, age, gender, income and payer type to ascertain if the physician would make an optimal investigator for your clinical trial. PDI also provides diagnosis codes so you know the demographic composition of patients being treated for the specific disease state you’re studying.

Meet FDA guidance

Ensure alignment with the latest guidance from the FDA regarding the need to increase participation from underrepresented racial and ethnic populations in clinical trials.

Diversify provider networks

Determine if the providers in your network best reflect the diversity of the areas they serve by comparing Census data for geographic areas of key physician specialties with their computed demographic mix.

Ensure equity


Sync diversity

Dummy Image

The diversity imperative

The COVID-19 pandemic shed a light on how racial and ethnic minority groups can be disproportionately affected by diseases and underrepresented in clinical trials. This webinar discusses the challenges in recruiting diverse clinical trial populations and how to overcome them, with an overview of PDI and sample output.

Dummy Image

Clinical trial diversity: Solutions for underrepresentation

This blog post digs deeper into the ethnic and racial disparities seen during COVID-19 vaccine clinical trials, the barriers to diversifying trials and potential solutions.